Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: Mechanisms and clinical relevance

Current Opinion in Virology

Volumn 8, Issue , 2014, Pages 104-108

  Götte, Matthias ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BALAPIRAVIR; DANOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; MERICITABINE; NONSTRUCTURAL PROTEIN 5B; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; RITONAVIR; RNA DIRECTED RNA POLYMERASE INHIBITOR; RNA POLYMERASE; SOFOSBUVIR; UNCLASSIFIED DRUG; VALOPICITABINE; NS-5 PROTEIN, HEPATITIS C VIRUS; NUCLEOTIDE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; DRUG BIOAVAILABILITY; GENE MUTATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; IC 50; IN VIVO STUDY; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REPLICON; REPLICON CELL; REVIEW; VIRUS MUTATION; VIRUS RESISTANCE; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DRUG EFFECTS; ENZYMOLOGY; GENETIC SELECTION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MISSENSE MUTATION; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MUTATION, MISSENSE; NUCLEOTIDES; SELECTION, GENETIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84907345433     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.07.010     Document Type: Review

References (25)

1. S.S. Carroll, J.E. Tomassini, M. Bosserman, K. Getty, M.W. Stahlhut, A.B. Eldrup, B. Bhat, D. Hall, A.L. Simcoe, R. LaFemina, and C.A. Rutkowski et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs J Biol Chem 278 2003 11979 11984 (Pubitemid 36800172)
2. G. Migliaccio, J.E. Tomassini, S.S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M.R. Bosserman, A. Ceccacci, L.F. Colwell, and R. Cortese et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro J Biol Chem 278 2003 49164 49170
3. S. Le Pogam, W.R. Jiang, V. Leveque, S. Rajyaguru, H. Ma, H. Kang, S. Jiang, M. Singer, S. Ali, K. Klumpp, and D. Smith et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance Virology 351 2006 349 359 (Pubitemid 44108072)
4. M.J. Sofia Nucleotide prodrugs for HCV therapy Antivir Chem Chemother 22 2011 23 49
5. M.J. Sofia Nucleotide prodrugs for the treatment of HCV infection Adv Pharmacol 67 2013 39 73
6. I. Gentile, N. Coppola, A.R. Buonomo, E. Zappulo, and G. Borgia Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus Expert Opin Investig Drugs 2014 1 13
7. G.M. Keating Sofosbuvir: a review of its use in patients with chronic hepatitis C Drugs 74 2014 1127 1146
8. K. Klumpp, V. Leveque, S. Le Pogam, H. Ma, W.R. Jiang, H. Kang, C. Granycome, M. Singer, C. Laxton, J.Q. Hang, and K. Sarma et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture J Biol Chem 281 2006 3793 3799 (Pubitemid 43847803)
9. A. Fung, Z. Jin, N. Dyatkina, G. Wang, L. Beigelman, and J. Deval Efficiency of incorporation and chain termination determines the inhibition potency of 2′-modified nucleotide analogs against hepatitis C virus polymerase Antimicrob Agents Chemother 58 2014 3636 3645
10. J. Deval, M.H. Powdrill, C.M. D'Abramo, L. Cellai, and M. Gotte Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase Antimicrob Agents Chemother 51 2007 2920 2928 (Pubitemid 47206231)
11. Z. Jin, V. Leveque, H. Ma, K.A. Johnson, and K. Klumpp NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent rna polymerase Proc Natl Acad Sci U S A 110 2013 E348 E357
12. L. Menendez-Arias Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase Virus Res 134 2008 124 146
13. J.M. Berke, L. Vijgen, S. Lachau-Durand, M.H. Powdrill, S. Rawe, E. Sjuvarsson, S. Eriksson, M. Gotte, E. Fransen, P. Dehertogh, and C. Van den Eynde et al. Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C cirus NS5B polymerase Antimicrob Agents Chemother 55 2011 3812 3820
14. A.M. Lam, C. Espiritu, S. Bansal, H.M. Micolochick Steuer, V. Zennou, M.J. Otto, and P.A. Furman Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA J Virol 85 2011 12334 12342
15. A.M. Lam, C. Espiritu, E. Murakami, V. Zennou, S. Bansal, H.M. Micolochick Steuer, C. Niu, M. Keilman, H. Bao, N. Bourne, and R.L. Veselenak et al. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of beta-d-2′-deoxy-2′-alpha-fluoro- 2′-beta-c-methylguanosine Antimicrob Agents Chemother 55 2011 2566 2575
16. R.T. Mosley, T.E. Edwards, E. Murakami, A.M. Lam, R.L. Grice, J. Du, M.J. Sofia, P.A. Furman, and M.J. Otto Structure of hepatitis C virus polymerase in complex with primer-template RNA J Virol 86 2012 6503 6511
17. J. Vermehren, and C. Sarrazin The role of resistance in HCV treatment Best Pract Res Clin Gastroenterol 26 2012 487 503
18. H. Mo HCV nucleoside NS5B polymerase inhibitors: antiviral activities and barriers to resistance among different HCV genotype and subtypes Antivir Therapy 19 Suppl. 1 2014 A21
19. X. Tong, L. Li, K. Haines, and I. Najera Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir Antimicrob Agents Chemother 58 2014 3105 3114
20. S. Ali, V. Leveque, S. Le Pogam, H. Ma, F. Philipp, N. Inocencio, M. Smith, A. Alker, H. Kang, I. Najera, and K. Klumpp et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479 Antimicrob Agents Chemother 52 2008 4356 4369
21. H. Dutartre, C. Bussetta, J. Boretto, and B. Canard General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues Antimicrob Agents Chemother 50 2006 4161 4169 (Pubitemid 44865161)
22. J.M. Pawlotsky, I. Najera, and I. Jacobson Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase Antivir Therapy 17 2012 411 423
23. M.H. Powdrill, E.P. Tchesnokov, R.A. Kozak, R.S. Russell, R. Martin, E.S. Svarovskaia, H. Mo, R.D. Kouyos, and M. Gotte Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance Proc Natl Acad Sci U S A 108 2011 20509 20513
24. R.M. Ribeiro, H. Li, S. Wang, M.B. Stoddard, G.H. Learn, B.T. Korber, T. Bhattacharya, J. Guedj, E.H. Parrish, B.H. Hahn, and G.M. Shaw et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate PLoS Pathog 8 2012 e1002881
25. X. Tong, S. Le Pogam, L. Li, K. Haines, K. Piso, V. Baronas, J.M. Yan, S.S. So, K. Klumpp, and I. Najera In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir J Infect Dis 209 2014 668 675